Next, we sought to investigate which signalling pathway was mainly responsible for USP12 downregulation in tumour cells by utilizing the inhibitors targeting the main pathways downstream of the oncogenic mutations or constitutively activated in NSCLC. This evidence concerns the gene USP12 and non-small cell lung carcinoma.